Site updated at Wednesday, 22 June 2016

Living with Dementia

Transdermal Rivastigmine

Drug Patch Gets OK for Severe Alzheimer’s

The FDA has expanded the indication for transdermal rivastigmine to include patients with severe Alzheimer’s disease.

The approval means that the transdermal agent is indicated for use in any Alzheimer’s patient, irrespective of disease stage or severity. The expanded indication is the first of its type for any Alzheimer’s drug, according to a statement… Drug Patch Gets OK for Severe Alzheimer’s   

Alzheimer’s Disease

behavioral signs1 - mediterranean and dash1 - parkinson's diagnosis1 - reverse cholesterol transport1 - symptoms of parkinson's disease1 - dsm iv3 - long-term memory1 - amyloid hypothesis1 - neuropsychological tests1 - apolipoprotein e41 - hearing1 - mitochondria1 - abstract thinking1 - electroencephalogram1 - cognitive tests1 - anti-hypertension medication1 - mri2 - ssri2 - hay fever1 - berrios and freeman1 - cognitive impairment10 - transdermal rivastigmine1 - good quality care1 - tau3 - delta-9-tetrahydrocannabinol1 - broken bones1 - penn medicine1 - olanzapine1 - alcohol-related brain damage1 - ftd1 -